Your browser doesn't support javascript.
loading
Over the counter naloxone needed to save lives in the United States.
Davis, Corey S; Carr, Derek.
Afiliación
  • Davis CS; Network for Public Health Law, Los Angeles, United States of America; Department of Public Health, Brody School of Medicine, East Carolina University, Greenville, United States of America. Electronic address: cdavis@networkforphl.org.
  • Carr D; Network for Public Health Law, Los Angeles, United States of America.
Prev Med ; 130: 105932, 2020 01.
Article en En | MEDLINE | ID: mdl-31770540
The United States continues to face a public health emergency of opioid-related harm, the effects of which could be dramatically reduced through increased access to the opioid antagonist naloxone. Unfortunately, naloxone is too often unavailable when and where it is most needed, partly due to its continued status as a prescription medication. Although states and the federal Food and Drug Administration (FDA) have acted to increase access to naloxone, these changes are insufficient to address this unprecedented crisis. In this Commentary, we argue that FDA can and should immediately reclassify naloxone from prescription-only to over-the-counter status, a change that could save hundreds if not thousands of lives in the United States every year.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: United States Food and Drug Administration / Naloxona / Antagonistas de Narcóticos País/Región como asunto: America do norte Idioma: En Revista: Prev Med Año: 2020 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: United States Food and Drug Administration / Naloxona / Antagonistas de Narcóticos País/Región como asunto: America do norte Idioma: En Revista: Prev Med Año: 2020 Tipo del documento: Article